Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $1,587 | $1,570 | $1,417 | $1,426 |
| - Cash | $363 | $382 | $269 | $124 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1,224 | $1,188 | $1,148 | $1,301 |
| Revenue | $165 | $157 | $148 | $159 |
| % Growth | 5% | 6% | -6.7% | – |
| Gross Profit | $87 | $80 | $74 | $64 |
| % Margin | 53% | 50.8% | 49.7% | 40.3% |
| EBITDA | $18 | $23 | $14 | $6 |
| % Margin | 11% | 14.7% | 9.4% | 3.9% |
| Net Income | $15 | $20 | $9 | $10 |
| % Margin | 9.1% | 12.9% | 5.8% | 6.3% |
| EPS Diluted | 0.4 | 0.54 | 0.23 | 0.27 |
| % Growth | -25.9% | 134.8% | -14.8% | – |
| Operating Cash Flow | $44 | $31 | $48 | $8 |
| Capital Expenditures | -$8 | -$34 | -$7 | -$7 |
| Free Cash Flow | $36 | -$4 | $41 | $1 |